Journals / Türk Biyokimya Dergisi / 2017 / Cilt: 42 - Sayı: 1

Assessment of macroprolactinemia rate in a training and research hospital from Turkey

Türkiye’de bir eğitim ve araştırma hastanesinde makroprolaktinemi oranının saptanması

Pages
87–91
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For the samples analysed on Cobas® e601 (n = 14,040)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Macroprolactinemia detection is important to avoid unneccessary tests and overtreatment.
📊
Key Findings & Data:In this study we aimed to determine the macroprolactinemia rate in our laboratory.Methods: Prolactin results of different patients analysed on two different immunoassay systems within two consecutive years were evaluated.
💡
Conclusion & Impact:For the samples analysed on Cobas® e601 (n = 14,040)
🔬Design:Research Article
📍Scope:138 samples
⚙️Variables:Domain Parameters

Abstract

Objective: Macroprolactinemia detection is important to avoid unneccessary tests and overtreatment. High prolactin levels require routine screening and clinicians must be aware of macroprolactinemia frequency encountered with the method in use. In this study we aimed to determine the macroprolactinemia rate in our laboratory.Methods: Prolactin results of different patients analysed on two different immunoassay systems within two consecutive years were evaluated. Analyses were performed on Beckman Coulter UniCel® DxI800 and Roche Cobas®e601 immunoassay systems. Samples for macroprolactin analysis were precipitated using polyethylene glycol (PEG) 6000. Post-PEG recovery 60% as negative for macroprolactin.Results: For the samples analysed on DxI800 (n = 14,958) hyperprolactinemia frequency was 8.1% (n = 1208). One of 138 samples submitted for macroprolactin analysis was positive, while three of them were in the gray-zone. For the samples analysed on Cobas® e601 (n = 14,040)

Özet

Amaç: Makroprolaktineminin saptanması gereksiz tetkik ve tedavinin önlenmesi açısından önemlidir. Yüksek prolaktin düzeyleri rutin tarama gerektirir ve klinisyenler kullanılan analiz yöntemiyle karşılaşılan makroprolaktinemi sıklığının farkında olmalıdır. Bu çalışmada laboratuvarımızda makroprolaktinemi oranının saptanması amaçlandı.Yöntemler: Ardışık iki yıl içerisinde farklı hastaların iki farklı immunoassay sisteminde çalışılmış prolaktin sonuçları incelendi. Analizler Beckman Coulter UniCel®DxI800 ve Roche Cobas® e601 immunoassay sistemlerinde yapıldı. Makroprolaktin istemi olan örnekler polietilen glikol (PEG) 6000 ile çöktürüldü. PEG çöktürme sonrası geri elde değeri %60 negatif olarak değerlendirildi.Bulgular: DxI 800'de çalışılmış örneklerde (n = 14.958) hiperprolaktinemi sıklığı%8.1'di (n = 1208). Makroprolaktin istemi olan 138 örneğin biri pozitifken üçü gri zondaydı. Cobas e601'de çalışılmış örneklerde (n = 14.040) hiperprolaktinemi sıklığı%13.9'du (n = 1954). Makroprolaktin istemi olan 238 örneğin onsekizi pozitifken 21 örnek gri zondaydı.Sonuç: Laboratuvarımızda kullanılmış iki immunoassay sisteminde makroprolaktinemi sıklığı açısından fark bulunmuştur. Ancak, her iki sistemde analiz edilen örneklerin farklı olması, jel filtrasyon kromatografisi ve heterofil antikor blokan tüp kullanılamamış olması çalışmanın limitasyonlarıdır

🔖

Cite This Article

YILMAZ, F. M., ERCAN, M., TURHAN, T., ERDOĞAN, S., TOPÇUOĞLU, C., AKBULUT, E. D. (2022). Assessment of macroprolactinemia rate in a training and research hospital from Turkey. Türk Biyokimya Dergisi, Cilt: 42 - Sayı: 1, 87–91. https://ajindex.com/articles/621005

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999;44(12 Suppl):1085–90
  2. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87:5410–5
  3. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005;42(Pt 3):175–92
  4. Yucel N, Eren N, Serin E. Prolactin levels discordant with clinical symptoms and Macroprolactin. Türk Nöroşirürji Dergisi 2007;17:33–9
  5. Kavanagh L, McKenna TJ, Fahie-Wilson MN, Gibney J, Smith TP. Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 2006;52:1366–72
  6. Beltran L, Fahie-Wilson MN, McKenna TJ, Kavanagh L, Smith TP. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008;54:1673–81
  7. Kasum M, Pavičić-Baldani D, Stanić P, Orešković S, Šarić J, Blajić J, et al. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 2014;183:28–32
  8. Silva AM, da Costa PM, Pacheco A, Oliveira JC, Freitas C. Assessment of macroprolactinemia by polyethylene glycol precipitation method. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2014;9:25–8
  9. McCudden CR, Sharpless JL, Grenache DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010;411:155–60
  10. Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013;27:725–42
  11. Sapin R, Simon C. False hyperprolactinemia corrected by the use of heterophilic antibody-blocking agent. Clin Chem 2001;47:2184–5
  12. Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem 2011;48(Pt 5):418–32
  13. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol 1999;51:119–26
  14. Hattori N, Ishihara T, Saiki Y, Shimatsu A. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol 2010;73:792–7
  15. Elenkova A, Genov N, Abadzhieva Z, Kirilov G, Vas